Entering text into the input field will update the search result below

Baxter: Some Real 'Buy' Appeal

May 03, 2022 12:07 PM ETBaxter International Inc. (BAX)4 Comments


  • I've been on a crusade for the past 2 weeks to highlight investable dividend-paying quality business as we're experiencing a market drop.
  • My work takes me now to revisit the company Baxter International, a quality business in the medical supply field. I wrote about the company several months ago.
  • The company has dropped significantly since my last piece. I'm putting Baxter on the "buy more" list.
  • Looking for more investing ideas like this one? Get them exclusively at iREIT on Alpha. Learn More »

Baxter Healthcare, Ireland

Simon Roughneen/iStock Editorial via Getty Images

Baxter international (NYSE:BAX) is a premium-valued healthcare equipment company that's been recovering from a valuation decline starting in 2015, following an EPS drop of almost 50% YoY. Since that time, Baxter has seen annual EPS growth rates

The company discussed in this article is only one potential investment in the sector. Members of iREIT on Alpha get access to investment ideas with upsides that I view as significantly higher/better than this one. Consider subscribing and learning more here.

This article was written by

Wolf Report profile picture

Wolf Report is a senior analyst and private portfolio manager with over 10 years generating value ideas in European and North American markets.

He is a contributing author for the investing group iREIT on Alpha where in addition to the U.S. market, he covers the markets of Scandinavia, Germany, France, UK, Italy, Spain, Portugal and Eastern Europe in search of reasonably valued stock ideas. Learn more.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of BAX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

While this article may sound like financial advice, please observe that the author is not a CFA or in any way licensed to give financial advice. It may be structured as such, but it is not financial advice. Investors are required and expected to do their own due diligence and research prior to any investment. Short-term trading, options trading/investment, and futures trading are potentially extremely risky investment styles. They generally are not appropriate for someone with limited capital, limited investment experience, or a lack of understanding for the necessary risk tolerance involved. The author's intent is never to give personalized financial advice, and publications are to be viewed as research and company interest pieces. The author owns the European/Scandinavian tickers (not the ADRs) of all European/Scandinavian companies listed in the articles. The author owns the Canadian tickers of all Canadian stocks written about.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (4)

Does the writer still think Baxter has appeal? What has this CEO done this year? Baxter is down 32% since the first of Jan. 2022. Time for a CEO change. I'm concerned that this leader is a good talker but is clueless.
freebird588 profile picture
BAX has changed a lot. How has your current BAX goal changed?
I respect the authors ability to publish several articles per day. However, I definitely miss Wolf's monthly portfolio update series or at least a quarterly update.

I am unable to follow through all the companies that Wolf writes about but lately I vehemently disagree with most of his "buy" ratings. I consider BAX to be 20% overvalued with no margin of safety at 72,05.
I did not see a projected year on when your $95 would hit. I am hopeful that you are correct but I don't see $95 for some time. Is it time for a new CEO?
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.